The average one-year price target for Citius Pharmaceuticals (NasdaqCM:CTXR) has been revised to $6.12 / share. This is an increase of 20.00% from the prior estimate of $5.10 dated April 25, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $6.06 to a high of $6.30 / share. The average price target represents an increase of 841.54% from the latest reported closing price of $0.65 / share.
What is the Fund Sentiment?
There are 45 funds or institutions reporting positions in Citius Pharmaceuticals. This is an increase of 7 owner(s) or 18.42% in the last quarter. Average portfolio weight of all funds dedicated to CTXR is 0.01%, an increase of 663.71%. Total shares owned by institutions increased in the last three months by 142.88% to 1,898K shares. 
The put/call ratio of CTXR is 0.03, indicating a bullish outlook.
What are Other Shareholders Doing?
Heights Capital Management holds 800K shares representing 2.95% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
Vanguard Capital Management holds 168K shares representing 0.62% ownership of the company.
Geode Capital Management holds 128K shares representing 0.47% ownership of the company. In its prior filing, the firm reported owning 120K shares , representing an increase of 6.09%. The firm decreased its portfolio allocation in CTXR by 65.60% over the last quarter.
XTX Topco holds 107K shares representing 0.40% ownership of the company. In its prior filing, the firm reported owning 16K shares , representing an increase of 85.14%. The firm increased its portfolio allocation in CTXR by 113.33% over the last quarter.
Vanguard Fiduciary Trust holds 78K shares representing 0.29% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
